Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024
Nearly 60% of patients with IgAN in the SPARTAN Study achieved complete remission when using FILSPARI as first-line treatment SPARTACUS Study, PROTECT open-label extension, and real-world evidence presentations highlight initial…
ROCKWOOL stärkt seine Position auf dem britischen Markt durch Übernahme von Wetherby Building Systems Ltd.
LONDON, Oct. 27, 2024 (GLOBE NEWSWIRE) -- Die dänische ROCKWOOL-Gruppe freut sich, die Übernahme von Wetherby Building Systems Ltd. bekanntzugeben. Die Übernahme ist ein wichtiger Meilenstein im Bestreben von ROCKWOOL,…
Empty Capsules Market to Grow at USD 4.96 Billion by 2031 |SkyQuest Technology
Westford, USA, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Empty Capsules Market size was valued at USD 2.89 billion in 2023 to USD 4.96 billion by 2031, growing at a CAGR…
Circuit Breaker Market to Exceed Market Valuation USD 9.4 Billion by 2031
Westford USA, Oct. 25, 2024 (GLOBE NEWSWIRE) -- SkyQuest projects that the global circuit breaker market will reach a value of USD 9.4 Billion by 2031, with a CAGR of…
Trinity Biotech Enters Oncology Space with Acquisition of Prostate Cancer Focused EpiCapture
DUBLIN, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the…
Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G
Statistically significant 68% (p
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
First to demonstrate clinical benefit in patients with chronic inducible urticaria (CIndU) in large, randomized, placebo-controlled study Favorable safety and tolerability Plan to advance CIndU into Phase 3 developmentCompany to…
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024
Long-term improvements observed in the quartet of findings defining disease modification supports atacicept’s potential to prevent kidney failure in patients with IgAN;Long-term results from the ORIGIN Phase 2b study were…
PetIQ, Inc. Announces Successful Completion of Acquisition by Bansk Group
EAGLE, Idaho and NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication, health and wellness company, today announced the…
Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months1Upon Fabhalta initiation, improvement observed in estimated glomerular filtration rate (eGFR) slope – a key measure of kidney function –…